S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
Log in
NASDAQ:RDNT

RadNet Competitors

$18.44
-0.33 (-1.76 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.41
Now: $18.44
$19.10
50-Day Range
$17.73
MA: $19.31
$21.10
52-Week Range
$5.81
Now: $18.44
$22.32
Volume216,024 shs
Average Volume184,604 shs
Market Capitalization$952.17 million
P/E RatioN/A
Dividend YieldN/A
Beta1.52

Competitors

RadNet (NASDAQ:RDNT) Vs. BNR, FLGT, GTH, CSTL, DMTK, and PSNL

Should you be buying RDNT stock or one of its competitors? Companies in the industry of "medical laboratories" are considered alternatives and competitors to RadNet, including Burning Rock Biotech (BNR), Fulgent Genetics (FLGT), Genetron (GTH), Castle Biosciences (CSTL), DermTech (DMTK), and Personalis (PSNL).

Burning Rock Biotech (NASDAQ:BNR) and RadNet (NASDAQ:RDNT) are both business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.

Profitability

This table compares Burning Rock Biotech and RadNet's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Burning Rock BiotechN/AN/AN/A
RadNet-0.98%-2.72%-0.37%

Valuation & Earnings

This table compares Burning Rock Biotech and RadNet's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Burning Rock BiotechN/AN/AN/AN/AN/A
RadNet$1.15 billion0.82$14.76 million$0.2963.59

RadNet has higher revenue and earnings than Burning Rock Biotech.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Burning Rock Biotech and RadNet, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Burning Rock Biotech00303.00
RadNet00203.00

Burning Rock Biotech currently has a consensus price target of $32.30, indicating a potential downside of 10.25%. RadNet has a consensus price target of $22.50, indicating a potential upside of 22.02%. Given RadNet's higher possible upside, analysts plainly believe RadNet is more favorable than Burning Rock Biotech.

Institutional and Insider Ownership

15.8% of Burning Rock Biotech shares are held by institutional investors. Comparatively, 67.5% of RadNet shares are held by institutional investors. 5.8% of RadNet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Fulgent Genetics (NASDAQ:FLGT) and RadNet (NASDAQ:RDNT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Fulgent Genetics and RadNet, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fulgent Genetics12202.20
RadNet00203.00

Fulgent Genetics currently has a consensus price target of $73.40, indicating a potential downside of 27.51%. RadNet has a consensus price target of $22.50, indicating a potential upside of 22.02%. Given RadNet's stronger consensus rating and higher possible upside, analysts plainly believe RadNet is more favorable than Fulgent Genetics.

Risk & Volatility

Fulgent Genetics has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Comparatively, RadNet has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500.

Institutional and Insider Ownership

33.4% of Fulgent Genetics shares are held by institutional investors. Comparatively, 67.5% of RadNet shares are held by institutional investors. 45.0% of Fulgent Genetics shares are held by company insiders. Comparatively, 5.8% of RadNet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Fulgent Genetics and RadNet's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fulgent Genetics35.31%43.81%36.82%
RadNet-0.98%-2.72%-0.37%

Valuation & Earnings

This table compares Fulgent Genetics and RadNet's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fulgent Genetics$32.53 million75.56$-410,000.00$0.025,063.00
RadNet$1.15 billion0.82$14.76 million$0.2963.59

RadNet has higher revenue and earnings than Fulgent Genetics. RadNet is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Summary

Fulgent Genetics beats RadNet on 7 of the 13 factors compared between the two stocks.

RadNet (NASDAQ:RDNT) and Genetron (NASDAQ:GTH) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Analyst Ratings

This is a breakdown of current ratings and target prices for RadNet and Genetron, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RadNet00203.00
Genetron00203.00

RadNet currently has a consensus price target of $22.50, indicating a potential upside of 22.02%. Genetron has a consensus price target of $19.50, indicating a potential downside of 20.70%. Given RadNet's higher possible upside, research analysts clearly believe RadNet is more favorable than Genetron.

Institutional & Insider Ownership

67.5% of RadNet shares are held by institutional investors. Comparatively, 19.6% of Genetron shares are held by institutional investors. 5.8% of RadNet shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares RadNet and Genetron's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RadNet-0.98%-2.72%-0.37%
GenetronN/AN/AN/A

Earnings and Valuation

This table compares RadNet and Genetron's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RadNet$1.15 billion0.82$14.76 million$0.2963.59
Genetron$45.68 million47.57$-95,470,000.00N/AN/A

RadNet has higher revenue and earnings than Genetron.

Summary

RadNet beats Genetron on 5 of the 9 factors compared between the two stocks.

RadNet (NASDAQ:RDNT) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Analyst Ratings

This is a breakdown of current ratings and target prices for RadNet and Castle Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RadNet00203.00
Castle Biosciences00503.00

RadNet currently has a consensus price target of $22.50, indicating a potential upside of 22.02%. Castle Biosciences has a consensus price target of $73.80, indicating a potential downside of 3.00%. Given RadNet's higher possible upside, research analysts clearly believe RadNet is more favorable than Castle Biosciences.

Risk & Volatility

RadNet has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, Castle Biosciences has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500.

Institutional & Insider Ownership

67.5% of RadNet shares are held by institutional investors. Comparatively, 66.4% of Castle Biosciences shares are held by institutional investors. 5.8% of RadNet shares are held by insiders. Comparatively, 39.7% of Castle Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares RadNet and Castle Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RadNet-0.98%-2.72%-0.37%
Castle Biosciences-5.30%-2.69%-2.05%

Earnings and Valuation

This table compares RadNet and Castle Biosciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RadNet$1.15 billion0.82$14.76 million$0.2963.59
Castle Biosciences$51.87 million29.56$5.28 million($0.81)-93.93

RadNet has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than RadNet, indicating that it is currently the more affordable of the two stocks.

Summary

RadNet beats Castle Biosciences on 9 of the 13 factors compared between the two stocks.

RadNet (NASDAQ:RDNT) and DermTech (NASDAQ:DMTK) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Analyst Ratings

This is a breakdown of current ratings and target prices for RadNet and DermTech, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RadNet00203.00
DermTech00603.00

RadNet currently has a consensus price target of $22.50, indicating a potential upside of 22.02%. DermTech has a consensus price target of $50.25, indicating a potential downside of 24.70%. Given RadNet's higher possible upside, research analysts clearly believe RadNet is more favorable than DermTech.

Risk & Volatility

RadNet has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, DermTech has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500.

Institutional & Insider Ownership

67.5% of RadNet shares are held by institutional investors. Comparatively, 51.4% of DermTech shares are held by institutional investors. 5.8% of RadNet shares are held by insiders. Comparatively, 16.5% of DermTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares RadNet and DermTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RadNet-0.98%-2.72%-0.37%
DermTech-577.75%-65.00%-58.37%

Earnings and Valuation

This table compares RadNet and DermTech's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RadNet$1.15 billion0.82$14.76 million$0.2963.59
DermTech$3.36 million389.16$-19,690,000.00($2.81)-23.75

RadNet has higher revenue and earnings than DermTech. DermTech is trading at a lower price-to-earnings ratio than RadNet, indicating that it is currently the more affordable of the two stocks.

Summary

RadNet beats DermTech on 9 of the 13 factors compared between the two stocks.

RadNet (NASDAQ:RDNT) and Personalis (NASDAQ:PSNL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Analyst Ratings

This is a breakdown of current ratings and target prices for RadNet and Personalis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RadNet00203.00
Personalis02702.78

RadNet currently has a consensus price target of $22.50, indicating a potential upside of 22.02%. Personalis has a consensus price target of $39.3333, indicating a potential upside of 27.58%. Given Personalis' higher possible upside, analysts clearly believe Personalis is more favorable than RadNet.

Risk & Volatility

RadNet has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, Personalis has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500.

Institutional & Insider Ownership

67.5% of RadNet shares are held by institutional investors. Comparatively, 65.5% of Personalis shares are held by institutional investors. 5.8% of RadNet shares are held by insiders. Comparatively, 8.2% of Personalis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares RadNet and Personalis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RadNet-0.98%-2.72%-0.37%
Personalis-45.13%-27.53%-19.66%

Earnings and Valuation

This table compares RadNet and Personalis' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RadNet$1.15 billion0.82$14.76 million$0.2963.59
Personalis$65.21 million18.41$-25,080,000.00($1.39)-22.18

RadNet has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than RadNet, indicating that it is currently the more affordable of the two stocks.

Summary

RadNet beats Personalis on 8 of the 14 factors compared between the two stocks.


RadNet Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BNR
Burning Rock Biotech
0.9$35.99-0.9%$3.66 billionN/A0.00
Fulgent Genetics logo
FLGT
Fulgent Genetics
1.2$101.26-1.5%$2.46 billion$32.53 million50.13Upcoming Earnings
News Coverage
GTH
Genetron
0.4$24.59-6.4%$2.17 billion$45.68 million0.00Gap Up
CSTL
Castle Biosciences
1.5$76.08-2.1%$1.53 billion$51.87 million-447.50Insider Selling
News Coverage
DMTK
DermTech
1.5$66.73-6.6%$1.31 billion$3.36 million-39.49Upcoming Earnings
PSNL
Personalis
1.8$30.83-2.8%$1.20 billion$65.21 million-29.08Earnings Announcement
Analyst Report
News Coverage
Gap Up
RNLX
Renalytix AI
0.9$22.80-2.2%$821.14 millionN/A-142.50Upcoming Earnings
PROG
Progenity
2.2$5.47-1.8%$298.78 millionN/A0.00Upcoming Earnings
XGN
Exagen
1.8$18.29-5.2%$231.41 million$40.39 million-1.49Gap Down
CNTG
Centogene
1.2$11.56-3.9%$229.59 million$54.64 million-7.92News Coverage
Gap Down
CELC
Celcuity
1.4$14.20-2.7%$146.32 millionN/A-16.71
Enzo Biochem logo
ENZ
Enzo Biochem
0.7$2.92-1.0%$139.85 million$76.02 million-6.79Upcoming Earnings
Biocept logo
BIOC
Biocept
1.2$6.03-3.5%$80.78 million$5.53 million-1.50Gap Down
ANPC
AnPac Bio-Medical Science
0.7$6.61-0.9%$74.04 million$1.56 million-4.08
Miragen Therapeutics logo
MGEN
Miragen Therapeutics
0.9$16.44-3.3%$64.25 million$4.46 million-1.54Gap Down
OpGen logo
OPGN
OpGen
1.3$2.29-3.5%$51.50 million$3.50 million-1.13Analyst Upgrade
Gap Down
PMD
Psychemedics
0.9$7.00-1.1%$38.69 million$37.68 million-10.14Upcoming Earnings
News Coverage
Cancer Genetics logo
CGIX
Cancer Genetics
0.6$6.51-1.4%$26.59 million$7.30 million-3.14Gap Up
AMS
American Shared Hospital Services
0.1$2.80-5.7%$16.13 million$20.60 million-28.00High Trading Volume
This page was last updated on 2/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.